Protein-based matrix interferences in ligand-binding assays

Bioanalysis

Volumn 6, Issue 8, 2014, Pages 1131-1140

  Gorovits, Boris ^a   McNally, Jim ^a   Fiorotti, Corinna ^a   Leung, Sheldon ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN ANTIBODY; BIOLOGICAL PRODUCT; DRUG ANTIBODY; HETEROPHILE ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G4; LIGAND; MONOCLONAL ANTIBODY; PROTEIN; REAGENT; RHEUMATOID FACTOR;

ANTIBODY AFFINITY; ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; BINDING ASSAY; CHEMICAL PARAMETERS; DRUG DETERMINATION; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOLOGICAL PARAMETERS; LIGAND BINDING; NONHUMAN; PHARMACOKINETICS; REVIEW; RHEUMATOID ARTHRITIS; CHEMISTRY; PROCEDURES;

HUMANS; IMMUNOASSAY; LIGANDS; PROTEINS;

EID: 84901046968     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.56     Document Type: Review

References (70)

1. Tate J, Ward G. Interferences in immunoassay. Clin. Biochem. Rev. 25(2), 105-120 (2004
2. Kricka LJ. Human anti-Animal antibody interferences in immunological assays. Clin. Chem. 45(7), 942-956 (1999
3. Nemzek JA, Newcomb DE, Call DR, Remick DG. Plasma interference in an enzyme-linked immunosorbant assay using a commercial matched antibody pair. Immunol. Invest. 28(4), 209-221 (1999
4. Hennig C, Rink L, Fagin U, Jabs WJ, Kirchner H. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J. Immunol. Methods 235(1-2), 71-80 (2000
5. Revelen R, Bordron A, Dueymes M, Youinou P, Arvieux J. False positivity in a cyto-ELISA for anti-endothelial cell antibodies caused by heterophile antibodies to bovine serum proteins. Clin. Chem. 46(2), 273-278 (2000
6. Stevenson L, Kelley M, Gorovits B et al. Consensus and recommendations of the L2 Global Harmonization Team, large molecule specific assay operation for pharmacokinetic ligand binding assays. AAPS J. (2013
7. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003
8. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol. Microbiol.Scand. 17(2), 172-188 (1940
9. Mannik M, Nardella FA, Sasso EH. Rheumatoid factors in immune complexes of patients with rheumatoid arthritis. Springer Semin. Immunopathol. 10(2-3), 215-230 (1988
10. Mewar D, Wilson AG. Autoantibodies in rheumatoid arthritis: A review. Biomed. Pharmacother. 60(10), 648-655 (2006
11. Lakos G. Interference in antiphospholipid antibody assays. Semin. Thromb. Hemost. 38(4), 353-359 (2012
12. Hennig C, Rink L, Kirchner H. Evidence for presence of IgG4 anti-immunoglobulin autoantibodies in all human beings. Lancet 355(9215), 1617-1618 (2000
13. Zack DJ, Stempniak M, Wong AL, Weisbart RH. Localization of an Fc-binding reactivity to the constant region of human IgG4. Implications for the pathogenesis of rheumatoid arthritis. J. Immunol. 155(10), 5057-5063 (1995
14. Rispens T, Ooievaar-De Heer P, Vermeulen E, Schuurman J, Van Der Neut Kolfschoten M, Aalberse RC. Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions. J. Immunol. 182(7), 4275-4281 (2009
15. Ito T, Kitahara K, Umemura T et al. A novel heterophilic antibody interaction involves IgG4. Scand. J. Immunol. 71(2), 109-114 (2010
16. Rispens T, De Vrieze H, De Groot E et al. Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testing. J. Immunol. Methods 375(1-2), 93-99 (2012
17. Araujo J, Zocher M, Wallace K, Peng K, Fischer SK. Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody. J. Pharm. Biomed. Anal. 55(5), 1041-1049 (2011
18. Tatarewicz S, Miller JM, Swanson SJ, Moxness MS. Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. J. Immunol. Methods 357(1-2), 10-16 (2010
19. Levinson SS. Antibody multispecificity in immunoassay interference. Clin. Biochem. 25(2), 77-87 (1992
20. Nossal GJ. Current concepts: Immunology. The basic components of the immune system. N. Engl. J. Med. 316(21), 1320-1325 (1987
21. Rubin RL, Theofilopoulos AN. Monoclonal autoantibodies reacting with multiple structurally related and unrelated macromolecules. Int. Rev. Immunol. 3(1-2), 71-95 (1988
22. Bouvet JP, Dighiero G. From natural polyreactive autoantibodies to a la carte monoreactive antibodies to infectious agents: Is it a small world after all? Infect. Immun. 66(1), 1-4 (1998
23. Bjerner J, Nustad K, Norum LF, Olsen KH, Bormer OP. Immunometric assay interference: Incidence and prevention. Clin. Chem. 48(4), 613-621 (2002
24. Kazmierczak SC, Catrou PG, Briley KP. Transient nature of interference effects from heterophile antibodies: Examples of interference with cardiac marker measurements. Clin. Chem. Lab. Med. 38(1), 33-39 (2000
25. Bolstad N, Warren DJ, Nustad K. Heterophilic antibody interference in immunometric assays. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 27(5), 647-661 (2013
26. Degn SE, Andersen SH, Jensen L, Thiel S, Jensenius JC. Assay interference caused by antibodies reacting with rat kappa light-chain in human sera. J. Immunol. Methods 372(1-2), 204-208 (2011
27. Bjerner J, Olsen KH, Bormer OP, Nustad K. Human heterophilic antibodies display specificity for murine IgG subclasses. Clin. Biochem. 38(5), 465-472 (2005
28. Hunter WM, Budd PS. Circulating antibodies to ovine and bovine immunoglobulin in healthy subjects: A hazard for immunoassays. Lancet 2(8204), 1136 (1980
29. Boscato LM, Stuart MC. Heterophilic antibodies: A problem for all immunoassays. Clin. Chem. 34(1), 27-33 (1988
30. Kaplan IV, Levinson SS. When is a heterophile antibody not a heterophile antibody? When it is an antibody against a specific immunogen. Clin. Chem. 45(5), 616-618 (1999
31. Rebello PR, Hale G, Friend PJ, Cobbold SP, Waldmann H. Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation 68(9), 1417-1420 (1999
32. Selby C. Interference in immunoassay. Ann. Clin. Biochem. 36(Pt 6), 704-721 (1999
33. Andersen DC, Koch C, Jensen CH, Skjødt K, Brandt J, Teisner B. High prevalence of human anti-bovine igg antibodies as the major cause of false positive reactions in two-site immunoassays based on monoclonal antibodies. J. Immunoassay Immunochem. 25(1), 17-30 (2004
34. Sjowall C, Kastbom A, Almroth G, Wettero J, Skogh T. Beware of antibodies to dietary proteins in 'antigen-specific' immunoassays! falsely positive anticytokine antibody tests due to reactivity with bovine serum albumin in rheumatoid arthritis (the Swedish TIRA project). J. Rheumatol. 38(2), 215-220 (2011
35. Kragstrup T, Vorup-Jensen T, Deleuran B, Hvid M. A simple set of validation steps identifies and removes false results in a sandwich enzyme-linked immunosorbent assay caused by anti-Animal IgG antibodies in plasma from arthritis patients. Springerplus 2(1), 263 (2013
36. Partridge MA, Pham J, Dziadiv O et al. Minimizing target interference in PK immunoassays: New approaches for low-pH-sample treatment. Bioanalysis 5(15), 1897-1910 (2013
37. Doucet J, Avrameas A. A novel method for quantitative measurement of a therapeutic monoclonal antibody in the presence of its target protein using enzymatic digestion. J. Pharm. Biomed. Anal. 52(4), 565-570 (2010
38. Moreau E, Philippe J, Couvent S, Leroux-Roels G. Interference of soluble TNF-Alpha receptors in immunological detection of tumor necrosis factor-Alpha. Clin. Chem. 42(9), 1450-1453 (1996
39. Bormer OP. Interference of complement with the binding of carcinoembryonic antigen to solid-phase monoclonalantibodies. J. Immunol. Methods 121(1), 85-93 (1989
40. Hansen TK, Fisker S, Hansen B et al. Impact of GHBP interference on estimatesof GH and GH pharmacokinetics. Clin. Endocrinol. 57(6), 779-786 (2002
41. Essink AW, Arkesteijn GJ, Notermans S. Interference of lysozyme in the sandwich enzyme-linked immunosorbent assay (ELISA). J. Immunol. Methods 80(1), 91-96 (1985
42. Watanabe M, Uchida K, Nakagaki K et al. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 581(10), 2017-2021 (2007
43. Meager A, Wadhwa M, Dilger P et al. Anti-cytokine autoantibodies in autoimmunity: Preponderance of neutralizing autoantibodies against interferon-Alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin. Exp. Immunol. 132(1), 128-136 (2003
44. Bakhiet M, Mustafa M, Zhu J et al. Induction of cytokines and anti-cytokine autoantibodies in cerebrospinal fluid (CSF) during experimental bacterial meningitis. Clin. Exp. Immunol. 114(3), 398-402 (1998
45. Armstrong JK, Hempel G, Koling S et al. Antibody against poly(ethylene glycol) adversely affects PEG-Asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110(1), 103-111 (2007
46. Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin. Drug Deliv. 9(11), 1319-1323 (2012
47. Hassan J, Feighery C, Bresnihan B, Whelan A. Prevalence of anti-Fab antibodies in patients with autoimmune and infectious diseases. Clin. Exp. Immunol. 89(3), 423-426 (1992
48. Fumia S, Goede JS, Fischler M et al. Human F(ab')2-containing immune complexes together with anti-hinge natural antibodies stimulate complement amplification in vitro and in vivo. Mol. Immunol. 45(10), 2951-2961 (2008
49. Osterland CK, Harboe M, HG. K. Anti-gamma-globulin factors in human sera revealed by enzymatic splitting of anti-Rh antibodies. Vox Sang. 8, 133-152 (1963
50. Brezski RJ, Luongo JL, Petrone D et al. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs. J. Immunol. 181(5), 3183-3192 (2008
51. Hirche TO, Stein J, Hirche H et al. Increased levels of anti-glycan antibodies in patients with cystic fibrosis. Eur. J. Med. Res. 16(9), 385-390 (2011
52. Galili U. Anti-Gal: An abundant human natural antibody of multiple pathogeneses and clinical benefits. Immunology 140(1), 1-11 (2013
53. Pochechueva T, Chinarev A, Spengler M et al. Multiplex suspension array for human anti-carbohydrate antibody profiling. Analyst 136(3), 560-569 (2011
54. Rieder F, Hahn P, Finsterhoelzl L et al. Clinical utility of anti-glycan antibodies in pediatric Crohn's disease in comparison with an adult cohort. Inflamm. Bowel Dis. 18(7), 1221-1231 (2012
55. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Clinical response to adalimumab: Relationship to anti-Adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66(7), 921-926 (2007
56. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 9(4), 418-435 (2003
57. Vennegoor A, Rispens T, Strijbis EM et al. Clinical releVance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult. Scler. 19(5), 593-600 (2013
58. Kelley M, Ahene AB, Gorovits B et al. Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation. AAPS J. 15(3), 646-658 (2013
59. Sailstad JM, Amaravidi L, Clements-Egan A et al. A White Paper-consensus and recommendations of a Global Harmonization Team on assessing the impact of immunogenicity on pharmacokinetic measurements. AAPS J. (2014) (In Press
60. Casesnoves A, Mauri M, Dominguez JR, Alfayate R, Pico AM. Influence of anti-insulin antibodies on insulin immunoassays in the autoimmune insulin syndrome. Ann. Clin. Biochem. 35(Pt 6), 768-774 (1998
61. Shankar G, DeVanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267-1281 (2008
62. Wang Y, Wei H, Pan Q et al. Identification and elimination of heterophilic antibody interference during antibody pair screening. Anal. Biochem. 430(1), 1-3 (2012
63. Bautista AC, Wullner D, Moxness M, Swanson SJ, Chirmule N, Jawa V. Impact of matrix-Associated soluble factors on the specificity of the immunogenicity assessment. Bioanalysis 2(4), 721-731 (2010
64. Bartels EM, Falbe Watjen I, Littrup Andersen E, Danneskiold-Samsoe B, Bliddal H, Ribel-Madsen S. Rheumatoid factor and its interference with cytokine measurements: Problems and solutions. Arthritis 2011, 741071 (2011
65. Rulander NJ, Cardamone D, Senior M, Snyder PJ, Master SR. Interference from anti-streptavidin antibody. Arch. Pathol. Lab. Med. 137(8), 1141-1146 (2013
66. de Jager W, Prakken BJ, Bijlsma JW, Kuis W, Rijkers GT. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J. Immunol. Methods 300(1-2), 124-135 (2005
67. Bartels EM, Ribel-Madsen S. Cytokine measurements and possible interference from heterophilic antibodies-problems and solutions experienced with rheumatoid factor. Methods 61(1), 18-22 (2013
68. Covinsky M, Laterza O, Pfeifer JD, Farkas-Szallasi T, Scott MG. An IgM lambda antibody to Escherichia coli produces false-positive results in multiple immunometric assays. Clin. Chem. 46(8 Pt 1), 1157-1161 (2000
69. Warren DJ, Bjerner J, Paus E, Bormer OP, Nustad K. Use of an in vivo biotinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies. Clin. Chem. 51(5), 830-838 (2005
70. Baird CL, Tan R, Fischer CJ, Victry KD, Zangar RC, Rodland KD. Reducing heterophilic antibody interference in immunoassays using single-chain antibodies. Anal. Biochem. 419(2), 333-335 (2011